Abstract:Abstract Introduction: Chromosomal instability (CIN) is a continuum of chromosomal gains and losses present in tumor cells. While increasing CIN is linked to poor patient outcomes in select cancers, the prognostic significance of CIN, and its association with molecular phenotypes and therapeutic response in advanced prostate cancer (PCa) is poorly understood. We characterize CIN in aggressive Pca by integrating DNA/RNA sequencing with detailed clinical information. Methods: From 4/2005-7/2021, 290 men with advanced PCa underwent IRB-approved tissue collection for tumoral RNA-sequencing and tumor/normal whole exome sequencing. DNA/RNA sequencing data for 328 libraries across 304 biopsies was processed using Turnkey Precision Oncology. CIN was measured using the weighted genome integrity index (wGII). Driver mutations (ETS fusions, SPOP, FOXA1 class 1, and CDK12 mutations), TP53 mutations and AR amplification status were determined. GSEA and EPIC were used for pathway/immune deconvolution. Associations with overall survival (OS) from the time of biopsy were determined via multivariable analysis (MVA). Results: 36 samples were from patients with localized disease (LD), 101 from metastatic hormone sensitive PCa (mHSPC) and 191 from metastatic castrate resistant PCa (mCRPC). wGII was associated with disease state: LD (median:0.28, IQR:[0.18-0.48]); mHSPCa (0.36, [0.21-0.58]); mCRPC (0.52, [0.35-0.62]) (p<0.001). TP53 loss was associated with wGII, independent of disease state (p<0.001). Strikingly, AR-amplifications were associated with increased wGII when controlled for disease state (p=2.2e-9). wGII was negatively associated with CD8+ T cell levels (R=-0.24,p=7.7e-4) and this remained significant on MVA adjusting for disease state and tumor purity (p=0.003). For mCRPC samples, GSEA of wGII-high tumors identified upregulation of EMT (q=6.8e-14) and downregulation of androgen response (q=2.7e-6). Additionally, wGII levels did not differ by prior exposure to enhanced hormonal agents or taxane therapy (p=0.82, p=0.70). Finally, high wGII was associated with worse OS when controlled for age, disease state, TP53 loss, AR amplification, and purity (HR: 3.28; 95% CI: 1.39-7.80, p=0.007). Conclusions: We identify CIN as one of the strongest genetic predictors of poor patient outcomes in metastatic PCa. Future research is needed to identify therapeutic vulnerabilities in this newly-described genetic subset of aggressive prostate cancers. Citation Format: Ryan J. Rebernick, Liat Hammer, Matthew McFarlane, Thomas Westbrook, Munna Hazime, Tanya Hammoud, Pin-en Chiu, Yi-Mi Wu, Dan Robinson, Daniel Eidelberg Spratt, Ajjai S. Alva, William C. Jackson, Zachery R. Reichert, Arul Chinnaiyan, Joshi J. Alumkal, Robert T. Dess, Marcin Cieslik. Association of chromosomal instability with poor prognosis in metastatic hormone sensitive and castrate-resistant prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2244.

Genome-wide Chromosomal Instability by Cell-Free DNA Sequencing Predicts Survival in Patients with Metastatic Breast Cancer.

Quantified CIN Score From Cell-free DNA as a Novel Noninvasive Predictor of Survival in Patients With Spinal Metastasis

Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse

Molecular Analysis of Cell-Free DNA to Identify Distinct Molecular Mutational Burden and Its Effect on First-Line Chemotherapy in Patients with NSCLC from a Phase III Trial.

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

Association of Clinical Outcomes in Metastatic Breast Cancer Patients with Circulating Tumour Cell and Circulating Cell-Free DNA.

Development of a Plasma Cell-Free DNA Chromosome Instabilities Assay for Early Cancer Detection and Treatment Response Monitoring of Multiple Tumor Types.

Low-pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple-negative breast cancer

Noninvasive Detection of Chromosomal Instability in Plasma Circulating Cell-Free DNA for Early Pan-Cancer Diagnosis Using Low-Pass Whole-Genome Sequencing.

The value of chromosome instability detected by low−pass whole−genome sequencing in preoperative prediction of sentinel lymph node metastasis in breast cancer

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer

High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer

Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC).

Chromosomal Instability of Circulating Tumor DNA Reflect Therapeutic Responses in Advanced Gastric Cancer.

Clinical and Phylogenetic Factors Affecting the Detection of Genomic Variants in Circulating Cell-Free DNA for Patient with Primary Breast Cancer.

Detection, Dynamic Monitoring, and Resistance Mechanism Exploration of Genomic Alterations in Circulating Cell Free Tumor DNA (ctdna) in Chinese Metastatic Breast Cancer (Mbc).

Paradoxical Relationship of Chromosomal Instability with Breast Cancer Outcome: Identification of a Good Prognostic ER Negative/HER2 Negative Breast Cancer Cohort with Extreme Chromosomal Instability.

Genome Instability-Derived Genes Are Novel Prognostic Biomarkers for Triple-Negative Breast Cancer

Chromosome instability functions as a potential therapeutic reference by enhancing chemosensitivity to BCL-XL inhibitors in colorectal carcinoma

Abstract 2244: Association of chromosomal instability with poor prognosis in metastatic hormone sensitive and castrate-resistant prostate cancer